Mochida Debuts Japanese Teriparatide Biosimilar
Biosimilar Of Eli Lilly’s Forteo Hits Japanese Market
Executive Summary
Mochida has launched the first Japanese teriparatide biosimilar rival to Eli Lilly’s blockbuster osteoporosis drug Forteo. The company is hoping for big sales for the injectable in the country where the government is aiming to rein in healthcare costs for its rapidly ageing population.
You may also be interested in...
Pfenex Expects To Be Alone With Teriparatide
Pfenex believes it and commercial partner Alvogen could enjoy an extended period as the only direct competitor to Eli Lilly’s Forteo teriparatide reference brand in the US.
Teriparatide Trickles In For Richter
Richter’s Terrosa biosimilar to Lilly’s Forsteo teriparatide brand made a modest start in Europe. But the Hungarian group still posted nine-month Pharmaceutical sales growth of 8.1%.
Japan Approves Biosimilar Teriparatide And Darbepoetin
Japan’s first biosimilar teriparatide has been approved for Mochida Pharmaceutical, while competition in the darbepoetin alfa arena looks set to step up following two recent authorizations.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: